Evidence map›Paper›PMID 35043526›Full record

ArticleChembiochem : a European journal of chemical biology2022

Selective Disruption of Survivin's Protein-Protein Interactions: A Supramolecular Approach Based on Guanidiniocarbonylpyrrole.

Dennis Aschmann, Cecilia Vallet, Sunil K Tripathi, Yasser B Ruiz-Blanco, Max Brabender, Carsten Schmuck, Elsa Sanchez-Garcia, Shirley K Knauer, Michael Giese

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dennis AschmannDepartment of Organic Chemistry, University of Duisburg-Essen, Universitätsstr. 7, 45141, Essen, Germany.
Cecilia ValletDepartment of Molecular Biology II, University of Duisburg-Essen, Universitätsstr. 5, 45141, Essen, Germany.
Sunil K TripathiComputational Biochemistry, University of Duisburg-Essen, Universitätsstr. 2, 45117, Essen, Germany.
Yasser B Ruiz-BlancoComputational Biochemistry, University of Duisburg-Essen, Universitätsstr. 2, 45117, Essen, Germany.ORCID 0000-0001-5400-4427
Max BrabenderDepartment of Molecular Biology II, University of Duisburg-Essen, Universitätsstr. 5, 45141, Essen, Germany.
Carsten SchmuckDepartment of Organic Chemistry, University of Duisburg-Essen, Universitätsstr. 7, 45141, Essen, Germany.
Elsa Sanchez-GarciaComputational Biochemistry, University of Duisburg-Essen, Universitätsstr. 2, 45117, Essen, Germany.ORCID 0000-0002-9211-5803
Shirley K KnauerDepartment of Molecular Biology II, University of Duisburg-Essen, Universitätsstr. 5, 45141, Essen, Germany.
Michael GieseDepartment of Organic Chemistry, University of Duisburg-Essen, Universitätsstr. 7, 45141, Essen, Germany.ORCID 0000-0001-6355-536X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting specific protein binding sites to interfere with protein-protein interactions (PPIs) is crucial for the rational modulation of biologically relevant processes. Survivin, which is highly overexpressed in most cancer cells and considered to be a key player of carcinogenesis, features two functionally relevant binding sites. Here, we demonstrate selective disruption of the Survivin/Histone H3 or the Survivin/Crm1 interaction using a supramolecular approach. By rational design we identified two structurally related ligands (L

Indexed as

Inhibitor of Apoptosis ProteinsBinding SitesCell ProliferationProtein BindingSurvivinInhibitor of Apoptosis ProteinsSurvivincancerCL-FEPmolecular recognitionsupramolecular chemistrysurvivin

Identifiers

PMID35043526
PMCPMC9303230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.